ID   Raji/A
AC   CVCL_C0HU
DR   cancercelllines; CVCL_C0HU
DR   Wikidata; Q114312766
RX   PubMed=25916297;
CC   Population: African; Nigerian.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene fusion; HGNC; HGNC:5477; IGH + HGNC; HGNC:7553; MYC; Name(s)=MYC-IGH (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Bone, jaw, maxilla; UBERON=UBERON_0002397.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0511 ! Raji
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 19-12-24; Version: 7
//
RX   PubMed=25916297; DOI=10.3760/cma.j.issn.0253-2727.2015.04.015; PMCID=PMC7342615;
RA   Zheng, Rong-Li
RA   Jiang, Yu-Jie
RA   Wang, Xin
RT   "The establishment of Raji drug-resistant cell line and analyses of
RT   prohibitin and miR-27a expression.";
RL   Zhonghua Xue Ye Xue Za Zhi 36:326-330(2015).
//